The estimated Net Worth of Management Associates V L.L... is at least 2.65 十億$ dollars as of 9 June 2016. Management L owns over 8,785,539 units of Catalent stock worth over 1,019,715,039$ and over the last 10 years Management sold CTLT stock worth over 1,635,027,231$.
Sign up
Management L CTLT stock SEC Form 4 insiders trading
Management has made over 6 trades of the Catalent stock since 2015, according to the Form 4 filled with the SEC. Most recently Management sold 17,100,705 units of CTLT stock worth 403,234,624$ on 9 September 2016.
The largest trade Management's ever made was selling 17,100,705 units of Catalent stock on 9 September 2016 worth over 403,234,624$. On average, Management trades about 9,416,743 units every 66 days since 2015. As of 9 June 2016 Management still owns at least 17,100,705 units of Catalent stock.
You can see the complete history of Management L stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Management L's mailing address?
Management's mailing address filed with the SEC is 345 Park Avenue, 345 Park Ave, New York, NY 10154, USA.
Insiders trading at Catalent
Over the last 10 years, insiders at Catalent have traded over 2,686,980,380$ worth of Catalent stock and bought 123,000 units worth 5,376,345$ . The most active insiders traders include Management Associates V L.L...、Peter Zippelius、Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of 22,866,018$. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth 39,429$.
What does Catalent do?
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
What does Catalent's logo look like?
Complete history of Management L stock trades at Catalent
Catalent executives and stock owners
Catalent executives and other stock owners filed with the SEC include:
-
John Chiminski,
Chairman of the Board, Chief Executive Officer -
Peter Buzy,
Chairman - Gene Therapy -
Alessandro Maselli,
Pres & COO -
John R. Chiminski,
Chairman & CEO -
Alessandro Maselli,
President, Chief Operating Officer -
Jonathan Arnold,
President - Oral Drug Delivery Solutions -
Wetteny Joseph,
Chief Financial Officer, Senior Vice President -
Steven Fasman,
Senior Vice President, General Counsel and Corporate Secretary -
Steven L. Fasman,
Sr. VP, Gen. Counsel & Corp. Sec. -
Karen A. Flynn,
Chief Commercial Officer -
Thomas P. Castellano,
Sr. VP & CFO -
Jack Stahl,
Lead Independent Director -
John Greisch,
Independent Director -
Donald Morel,
Independent Director -
Gregory Lucier,
Independent Director -
Rosemary Crane,
Independent Director -
Rolf Classon,
Independent Director -
J. Martin Carroll,
Independent Director -
Christa Kreuzburg,
Independent Director -
Madhavan Balachandran,
Independent Director -
Peter Zippelius,
Independent Director -
Z Mahdavi,
Vice President of Open Innovation, Biologics, Cell and Gene Therapy -
Jim Walter,
Vice President of Operations for its Oral and Specialty Delivery business -
Scott Gunther,
Senior Vice President - Quality & Regulatory Affairs -
Mike Grippo,
Senior Vice President - Strategy and Corporate Development -
Charles Lickfold,
Senior Vice President, Chief Information Officer -
Ricardo Pravda,
Chief Human Resource Officer, Senior Vice President -
Ricci Whitlow,
President - Clinical Supply Services -
Aristippos Gennadios,
President - Softgel Technologies -
Mario Gargiulo,
Region President, Biologics – Europe -
Karen Flynn,
President - Biologics and Chief Commercial Officer -
Manja Boerman,
President - Cell & Gene Therapy -
Ricardo Pravda,
Sr. VP & Chief HR Officer -
Michael J. Grippo,
Sr. VP of Strategy & Corp. Devel. -
Paul Surdez,
VP of Investor Relations -
Julien Meissonnier,
VP & Chief Scientific Officer -
Ricky Hopson,
VP & Chief Accounting Officer -
Sharon Johnson,
See Remarks -
Uwe Roehrhoff,
Director -
James Quella,
Director -
Management Associates V L.L...,
-
Melvin D Booth,
Director -
Matthew M Walsh,
See Remarks -
Christine Dolan,
See Remarks -
Stephen Leonard,
See Remarks -
Michael J Grippo,
SVP, Strategy & Corp. Dev. -
William Downie,
See Remarks -
Lance Miyamoto,
See Remarks -
Barry Littlejohns,
President, Biologics & SDD -
Paul W Jr Hegwood,
President, CSS -
Scott Houlton,
See Remarks -
Healthcare Partners L.L.C. ...,
10% owner -
Nielsen Kurt,
See Remarks -
Michael J Barber,
Director -
Michael Hatzfeld,
Chief Accounting Officer -
Thomas P Castellano,
SVP, Chief Financial Officer -
Frank A Damelio,
Director -
Michelle R Ryan,
Director -
Stephanie Okey,
Director -
Thomas W Hawkeswood,
Pres. Pharma Prod Delivery Div -
Karen Murphy Santiago,
VP & Chief Accounting Officer -
Patricia Hunt,
Pres. Consumer Health Div -
Michael A. Riley,
Pres. Bio Product Delivery Div -
Lorenzo Carletti,
SVP Global Ops Ph & Cons Hlth -
Kay A Schmidt,
SVP, Enterprise Functions -
Lisa Evoli,
SVP, Chief HR Officer -
Matti Masanovich,
SVP, Chief Financial Officer -
Ricardo Zayas,
SVP, Operations, Biologics NA -
Joseph Anthony Ferraro,
SVP, General Counsel, CCO -
Steven Barg,
Director -
David Mc Erlane,
Group President, Biologics -
Ricky Hopson,
Pres. BioProduct Delivery, CoS